An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2

NCT02756832 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1409

Last updated 2019-07-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2 (T2DM) at Month 6.

Conditions

Interventions

DRUG

Alogliptin Benzoate

Alogliptin benzoate tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-20
Primary Completion
2018-04-28
Completion
2018-04-28
FDA Drug
Yes

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756832 on ClinicalTrials.gov